These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2510677)

  • 21. Development and evaluation of anisoylated plasminogen streptokinase activator complex (APSAC) as a second generation thrombolytic agent.
    Anderson JL
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):22B-27B. PubMed ID: 3312369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reperfusion, patency and reocclusion with anistreplase (APSAC) in acute myocardial infarction.
    Anderson JL
    Am J Cardiol; 1989 Jul; 64(2):12A-17A; discussion 24A-26A. PubMed ID: 2662737
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group.
    Lancet; 1992 Mar; 339(8796):753-70. PubMed ID: 1347801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Angiographic assessment of patency and reocclusion: preliminary results of the Dutch APSAC Reocclusion Multicenter Study (ARMS).
    Visser RF
    Clin Cardiol; 1990 Mar; Suppl 5():V45-7; discussion V67-72. PubMed ID: 2182241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tolerance and complications in a multicenter trial of intravenous APSAC and intracoronary streptokinase in acute myocardial infarction.
    Rothbard RL; Anderson JL; Fitzpatrick PG; Hakworthy RA; Sorensen SG; Marder VJ
    Clin Cardiol; 1990 Mar; Suppl 5():V11-4; discussion V27-32. PubMed ID: 2182234
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics, thrombolytic efficacy and hemorrhagic risk of different streptokinase regimens in heparin-treated acute myocardial infarction.
    Col JJ; Col-De Beys CM; Renkin JP; Lavenne-Pardonge EM; Bachy JL; Moriau MH
    Am J Cardiol; 1989 May; 63(17):1185-92. PubMed ID: 2653017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of coagulation and fibrinolysis after intravenous anisoylated plasminogen streptokinase activator complex or heparin in patients with acute myocardial infarction. A Belgian multicentre study.
    Renkin J; Beys CC; Lavenne-Pardonge E; Pintens H; Col J
    Drugs; 1987; 33 Suppl 3():253-60. PubMed ID: 3315603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomised placebo-controlled pilot dose-response study with anisoylated plasminogen streptokinase activator complex in acute coronary artery occlusions.
    Leizorovicz A; Durrieu G; Boissel JP
    Drugs; 1987; 33 Suppl 3():133-7. PubMed ID: 3315579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of left ventricular function in a randomised study of intravenous anisoylated plasminogen streptokinase activator complex versus heparin in acute myocardial infarction. Preliminary results of the European Multicentre Study (Belgian Centres).
    Taeymans Y; Materne P
    Drugs; 1987; 33 Suppl 3():216-20. PubMed ID: 3315594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fibrinogen concentration and coronary artery reperfusion after intravenous anisoylated plasminogen streptokinase activator complex or intracoronary streptokinase therapy.
    Marder VJ; Kinsella PA; Brown MJ
    Drugs; 1987; 33 Suppl 3():237-41. PubMed ID: 3315601
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and side effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.
    Monassier JP; Hanssen M
    Drugs; 1987; 33 Suppl 3():282-5. PubMed ID: 3315608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid lysis of coronary artery thrombi with anisoylated plasminogen: streptokinase activator complex. Treatment by bolus intravenous injection.
    Marder VJ; Rothbard RL; Fitzpatrick PG; Francis CW
    Ann Intern Med; 1986 Mar; 104(3):304-10. PubMed ID: 3511819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dose-ranging studies of anisoylated plasminogen streptokinase activator complex. Studies in healthy volunteers and in patients with acute myocardial infarction.
    Marder VJ; Rothbard RL; Fitzpatrick PG; Francis CW; Norry EC
    Drugs; 1987; 33 Suppl 3():124-32. PubMed ID: 3315577
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Anisoylated plasminogen streptokinase complex during the acute phase of myocardial infarction. Results of a multicenter double-blind study versus heparin].
    Cassagnes J; Bassand JP; Machecourt J; Lusson JR; Anguenot T; Borel E; Vacher D; Denis B; Maurat JP; Jallut H
    Arch Mal Coeur Vaiss; 1990 Apr; 83(4):453-60. PubMed ID: 2111665
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [New thrombolytic agents in myocardial infarction].
    Charbonnier B; Lang M; Brochier M
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Study finds similar reperfusion rates with intravenous APSAC and intracoronary streptokinase in acute myocardial infarction.
    Clin Pharm; 1988 Sep; 7(9):634, 638. PubMed ID: 3071445
    [No Abstract]   [Full Text] [Related]  

  • 37. Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. AIMS Trial Study Group.
    Lancet; 1990 Feb; 335(8687):427-31. PubMed ID: 1968167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Invasive reperfusion study. II. Multicentre European randomized trial of anistreplase vs streptokinase in acute myocardial infarction.
    Pacouret G; Charbonnier B; Curien ND; Monassier JP; Cribier A; Materne P; Brochier ML; Letac R; Hanssen M; Sacrez A
    Eur Heart J; 1991 Feb; 12(2):179-85. PubMed ID: 2044551
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and tolerance data from the Belgian multicentre study of anisoylated plasminogen streptokinase activator complex versus heparin in acute myocardial infarction.
    Bossaert LL
    Drugs; 1987; 33 Suppl 3():287-92. PubMed ID: 3315610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic effects of anisoylated plasminogen streptokinase activator complex and streptokinase therapy in acute myocardial infarction. Coagulation aspects of the Dutch Invasive Reperfusion Study.
    Hoffmann JJ; Bonnier JJ; de Swart JB; Custers P; Vijgen M
    Drugs; 1987; 33 Suppl 3():242-6. PubMed ID: 3315602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.